|
Editorial
|
|
A tale of two trials: selectively replicating herpesviruses for brain tumors
|
815
|
|
DH Kirn
|
| Full Article PDF
|
 |
|
|
Inherited disease
|
Anti-inflammatory action of type I interferons deduced from mice expressing interferon 
|
817
|
|
L Boscá, OG Bodelón, S Hortelano, A Casellas & F Bosch
|
| Abstract Full Article PDF
|
| |
|
|
Nonviral transfer technology
|
|
Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo
|
826
|
|
L Heller, MJ Jaroszeski, D Coppola, C Pottinger, R Gilbert & R Heller
|
| Abstract Full Article PDF
|
| |
|
|
Cell based therapy
|
|
Efficiency of transgenic T cell generation from gene-marked cultured human CD34+ cord blood cells is determined by their maturity and the cytokines present in the culture medium
|
830
|
|
B Verhasselt, E Naessens, M De Smedt & J Plum
|
| Abstract Full Article PDF
|
| |
|
Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity
|
837
|
|
YS Kim, CH Sonn, S-G Paik & ALM Bothwell
|
| Abstract Full Article PDF
|
| |
|
|
Acquired diseases
|
|
Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model
|
844
|
|
Y Horiguchi, WA Larchian, R Kaplinsky, WR Fair & WDW Heston
|
| Abstract Full Article PDF
|
| |
|
Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors
|
852
|
|
C Guha, U Guha, S Tribius, A Alfieri, D Casper, P Chakravarty, W Mellado, TK Pandita & B Vikram
|
| Abstract Full Article PDF
|
| |
|
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
|
859
|
|
R Rampling, G Cruickshank, V Papanastassiou, J Nicoll, D Hadley, D Brennan, R Petty, A MacLean, J Harland, E McKie, R Mabbs & M Brown
|
| Abstract Full Article PDF
|
| |
|
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial
|
867
|
|
JM Markert, MD Medlock, SD Rabkin, GY Gillespie, T Todo, WD Hunter, CA Palmer, F Feigenbaum, C Tornatore, F Tufaro & RL Martuza
|
| Abstract Full Article PDF
|
| |
|
|
Viral transfer technology
|
|
Adenoviral vector which delivers FasL–GFP fusion protein regulated by the tet-inducible expression system
|
875
|
|
S Rubinchik, R Ding, AJ Qiu, F Zhang & J Dong
|
| Abstract Full Article PDF
|
| |
|
Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors
|
886
|
|
DS Strayer, RJ Pomerantz, M Yu, M Rosenzweig, M BouHamdan, S Yurasov, RP Johnson & H Goldstein
|
| Abstract Full Article PDF
|
| |
|
Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers
|
896
|
|
U Modlich, CW Pugh & R Bicknell
|
| Abstract Full Article PDF
|
| |
| |
| |
